Navigation Links
Stem Cell Treatment Leader Tiantan Puhua Adds Experienced International Medical Staff for Expanding Numbers of Patients
Date:1/7/2009

BEIJING, Jan. 7 /PRNewswire/ -- Tiantan Puhua Hospital Stem Cells Center (http://www.stemcellspuhua.com), the worldwide leader in using stem cells to effectively treat neurological disorders, announced today six new globally experienced additions to its medical and research staff that significantly expand the hospital's treatment capabilities for growing numbers of incoming international patients. The six senior doctors include the distinguished Dr. Jiang Ping, who was named Chief Scientific Advisor of Tiantan Puhua. Dr. Jiang lectured at and received his postgraduate degree from Harvard Medical School in 1997. He also worked for several years in the Department of Tumor Therapy at Massachusetts General Hospital, and is currently Director at the Laboratory of Stem Cell and Genetic Engineering at the Wistar Institute of the University of Pennsylvania. As well, Tiantan Puhua named Dr. Zhou Jingli, a recent visiting scholar at Michigan State University, as Chief Neurologist in Beijing. Dr. Zhou is joined by neurologists Dr. Li Miaomiao, who has treated dozens of international patients in China, and Dr. Song Changua. Dr. Song, who recently returned from a research stint at Japan's Kansai Medical University, where he received his Ph.D., has published his stem cell research in Western scientific journals such as "Immunobiology." Renowned Chinese neurosurgeons Dr. Han Jiebing and Dr. Yu Yong, both of whom have published research findings in Chinese medical journals, joined Tiantan Puhua's experienced medical team to deepen the hospital's stem cell treatment capabilities. Dr. Yu also recently returned to China after earning a degree at Japan's Nagoya City University Medical School where he worked at the university's Medical School Hospital, bringing back a wealth of experience in using stem cells for clinical applications.

Dr. Sherwood Yang, Vice President of Tiantan Puhua Hospital, said, "We are proud to be adding the world's most skilled medical professionals to our team to treat the increasing numbers of those suffering from neurological illnesses worldwide, but restricted from receiving treatment in their own countries." Dr. Yang continued, "I am confident that our ever-improving treatment programs, experienced doctors, outstanding support personnel, and stringent scientific protocols represent top quality in stem cell treatment, and are things not easily replicated."

About Tiantan Puhua Neurosurgical Hospital

Tiantan (Temple of Heaven) Puhua Neurosurgical Hospital, a Hospital under TP Biomedical Ltd., is a world-class neurological treatment facility in Beijing that is gaining renown as the world's foremost center for treatment of Parkinson's disease, brain injury, Cerebral palsy, Batten disease, and a range of other neurological disorders through its groundbreaking stem cell therapy. The Hospital collaborates with the Stem Cells Research Center of Peking University, which is the foremost stem cells research center in China. There, stem cells are cultured for clinical application. To date, Tiantan Puhua Hospital has treated with stem cells over 150 international patients suffering from a range of neurological disorders. More details about Tiantan Puhua Hospital can be found on the website http://www.stemcellspuhua.com.

    For inquiries, please contact:

    Vivian Wang - International Department
    Tel: +86 10 67035566 ext. 526
    Email: Vivian@stemcellspuhua.com
    Tiantan Puhua Neurosurgical Hospital
    Tiantan Nanli, Beijing 100050, CHINA

More information can also be found on China's leading stem cells news site: http://www.stemcellschina.com

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Tiantan Puhua Neurosurgical Hospital
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment
2. MRI Emerges As Vital Resource in Treatment of Back Pain
3. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
4. Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL
5. Novel Therapeutic Approaches May Transform Treatment and Improve Patient Outcomes in Several Platelet Disorders
6. VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology
7. S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis
8. Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma
9. Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout
10. Medarex Announces Initiation of Phase 1b Clinical Development Program with MDX-1106 for the Treatment of Cancer
11. New Cancer Treatment Shrinks Pancreatic Tumor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... , Feb 17, 2017 Research and Markets ... Business Report" report to their offering. ... The report provides separate comprehensive analytics for the US, ... , Asia-Pacific , Latin America ... the period 2015 through 2022. Also, a six-year historic analysis is provided ...
(Date:2/17/2017)... ST. LOUIS , Feb. 17, 2017   ... hospitals, has announced a new partnership with Engage ... the United States . FormFast will serve ... part of Engage,s implementations with MEDITECH .  ... that provides essential functionality to complement and enhance the ...
(Date:2/17/2017)... 17, 2017 On Thursday, February ... edged lower at the closing bell, while the Dow ... 20,000 benchmark. Moreover, five out of nine sectors ended ... yesterday,s market sentiment, Stock-Callers.com assessed the following Medical Appliances ... (NYSE: SNN ), ABIOMED Inc. (NASDAQ: ...
Breaking Medicine Technology:
(Date:2/17/2017)... ... 2017 , ... Like most hospitals across the nation, Onslow Memorial Hospital is ... Hospital Readmission Reduction Program (HRRP), the return of a patient to the hospital within ... nation. While many providers are struggling to leverage limited resources and technology, Onslow Memorial ...
(Date:2/17/2017)... ... February 17, 2017 , ... The Mason ... to families and business owners in and around the Hampton Roads metropolitan region, ... prevent all forms of domestic violence. , There are multiple categories of domestic ...
(Date:2/16/2017)... ... February 17, 2017 , ... Harsha Chigurupati knows the ... research, development and clinical trials, the founder of Chigurupati Technologies has invented India’s ... FDA approved ingredients that when infused into alcohol, protect the consumer’s liver and ...
(Date:2/16/2017)... ... February 17, 2017 , ... Teaching nursing care of vulnerable children is the ... (pediatrics) is being created with the support of the Hearst Foundations. An initiative of ... will address what has been identified as a critical gap in preparing the next ...
(Date:2/16/2017)... ... February 16, 2017 , ... As a reflection of ... NWH has achieved Magnet® recognition for the second time, announced by ... American Nurses Credentialing Center’s Magnet Recognition Program® distinguishes organizations that meet rigorous standards ...
Breaking Medicine News(10 mins):